CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project aims to develop a blood-based epigenetic tool that identifies patients with type 2 diabetes who will respond to metformin therapy. By predicting treatment outcomes, this tool seeks to optimize diabetes management and improve patient care.
The prevalence of diabetes will rise to ~592 million in 2035.
Type 2 diabetes (T2D) is a leading cause of death through its vascular complications.
High glucose increases the risk for complications, and thereby suffering for patients and costs for society.
It is important that patients with T2D receive an optimal therapy that lowers blood glucose.
Metformin is first-line T2D therapy.
However, ~30% of patients do not respond to metformin.
Currently, there are no biomarkers that predict the respon…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
